Understanding how fatty acids affect immune responses in pancreatic tumors
Fatty acid signaling in the pancreatic tumor microenvironment
This study is looking at how certain fats in the body affect the way immune cells behave around pancreatic cancer, with the hope of finding new ways to help the immune system fight the disease better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10848436 on NIH RePORTER |
What this research studies
This research investigates the role of fatty acid signaling in the pancreatic tumor microenvironment, particularly focusing on how it influences immune cell behavior. By examining the mechanisms of immune evasion in pancreatic ductal adenocarcinoma (PDAC), the study aims to identify potential targets for immune-modulatory therapies. The approach involves analyzing the interactions between cancer cells and immune cells, specifically looking at how certain proteins and fatty acids affect tumor growth and immune suppression. Patients may benefit from insights that could lead to new treatment strategies aimed at enhancing the immune response against pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel immune-modulatory treatments.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve immune responses in patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in using immune-modulatory therapies for pancreatic cancer, suggesting that this approach could be beneficial.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Sherman, Mara H. — Sloan-Kettering Inst Can Research
- Study coordinator: Sherman, Mara H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.